Market closedNon-fractional
Armata Pharmaceuticals/ARMP
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Armata Pharmaceuticals
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. Th Company is engaged in developing and advancing a pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Its two lead candidates addresses both chronic and acute bacterial infections. The Company's first lead candidate focused primarily on chronic bacterial infections is the clinical phage candidate for Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection.
Ticker
ARMP
Sector
Healthcare
Trading on
AMEX
Industry
Biotechnology & Drugs
Headquarters
Los angeles, United States
Employees
66
Website
www.armatapharma.com
ARMP Metrics
BasicAdvanced
$98M
Market cap
-
P/E ratio
-$2.20
EPS
0.83
Beta
-
Dividend rate
Price and volume
Market cap
$98M
Beta
0.83
52-week high
$5.26
52-week low
$1.07
Average daily volume
0.32
Financial strength
Current ratio
0.379
Interest coverage (TTM)
-1.11%
Management effectiveness
Return on assets (TTM)
-69.46%
Return on investment (TTM)
-235.17%
Valuation
Price to revenue (TTM)
20.928
Growth
Revenue change (TTM)
-7.28%
Earnings per share change (TTM)
-86.33%
3-year revenue growth (CAGR)
76.55%
What the Analysts think about ARMP
Analyst Ratings
Majority rating from 2 analysts.
ARMP Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$900K
-40.00%
Net income
-$25M
26.26%
Profit margin
-2,777.77%
110.44%
ARMP Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.10
-$0.86
-$0.55
-$0.69
-
Expected
-$0.38
-$0.31
-$0.35
-$0.31
-$0.44
Surprise
-73.33%
177.42%
57.14%
122.58%
-
ARMP News
AllArticlesVideos
Armata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection
PRNewsWire·2 weeks ago
Armata Pharmaceuticals Announces Presentation at Viruses of Microbes 2024
PRNewsWire·2 weeks ago
Armata Pharmaceuticals Announces First Quarter 2024 Results and Provides Corporate Update
PRNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Armata Pharmaceuticals stock?
Armata Pharmaceuticals (ARMP) has a market cap of $98M as of July 26, 2024.
What is the P/E ratio for Armata Pharmaceuticals stock?
The price to earnings (P/E) ratio for Armata Pharmaceuticals (ARMP) stock is 0 as of July 26, 2024.
Does Armata Pharmaceuticals stock pay dividends?
No, Armata Pharmaceuticals (ARMP) stock does not pay dividends to its shareholders as of July 26, 2024.
When is the next Armata Pharmaceuticals dividend payment date?
Armata Pharmaceuticals (ARMP) stock does not pay dividends to its shareholders.
What is the beta indicator for Armata Pharmaceuticals?
Armata Pharmaceuticals (ARMP) has a beta rating of 0.83. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Armata Pharmaceuticals stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.